Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors

The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.

Trial Details

NCT ID
NCT06773507
Phase
PHASE1
Sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • BC008-1A 900mg
  • BC008-1A 1200mg
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Patients with inoperable, locally advanced or metastatic esophageal squamous cell carcinoma confirmed by histopathology or cytology. Those who have…
  • Patients with non-small cell lung cancer (squamous cell carcinoma and adenocarcinoma) confirmed by histology or cytology, who have failed standard …
  • Sign a written informed consent form before any study-specific procedures and be able to follow the visit schedules and related procedures stipulat…
  • Male or female patients aged ≥ 18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →